Gastroesophageal Junction Adenocarcinoma
📧 Sign up to get email alerts when something new happens for Gastroesophageal Junction Adenocarcinoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-01-28Clinical Trial Update: Registry Platform Gastric/Esophageal Cancer (SAPHIR)
This Clinical Trial Update reports an ongoing registry platform trial SAPHIR addressing gastric and esophageal cancers, currently recruiting…
-
CLINICAL_TRIALS research · 2026-01-28Clinical Trial Update: Perioperative Ivonescimab Plus S-1 and Oxaliplatin (SOX) for Locally Advanced Gastric or GEJ Adenocarcinoma [Phase 2]
This ClinicalTrials.gov entry describes a Phase 2 perioperative trial of Ivonescimab plus S-1 and oxaliplatin (SOX) for locally advanced gas…
-
CLINICAL_TRIALS research · 2026-01-28Clinical Trial Update: A Study of KK2269 in Adult Participants With Solid Tumors [Phase 1]
Phase 1 study update for KK2269 in adults with solid tumors; the trial is currently recruiting. Indications include gastric adenocarcinoma, …
-
CLINICAL_TRIALS research · 2026-01-27Clinical Trial Update: ASKB589 in Combination With CAPOX and PD-1 Inhibitor in Patients With Advanced or Metastatic GC/GEJ Adenocarcinoma [Phase 3]
Clinical trial update for ASKB589 in combination with CAPOX and a PD-1 inhibitor for advanced or metastatic gastric/gastroesophageal junctio…
-
CLINICAL_TRIALS other · 2026-01-27Clinical Trial Update: Adebrelimab Combined With Induction Chemotherapy or SHR-8068 for Mismatch Repair-Deficient/Microsatellite Instability-High (dMMR/MSI-H) Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma：A Randomized, Non-comparative Phase 2 Study [Phase 2]
A Phase 2 trial update describing a randomized study of Adebrelimab with induction chemotherapy or SHR-8068 in locally advanced dMMR/MSI-H g…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-01-23Clinical Trial Update: Perioperative Treatment of Combined SOX With Apatinib and Camrelizumab for Oesophagogastric Cancer [Phase 2, Phase 3]
A perioperative trial investigating the combination of SOX chemotherapy with Apatinib and Camrelizumab for gastric and gastroesophageal junc…
-
CLINICAL_TRIALS trial_result · 2026-01-23Clinical Trial Update: LM-108 in Combination With Toripalimab Versus Paclitaxel Injection for the Treatment of Subjects With CCR8-Positive Gastric and Gastroesophageal Junction Adenocarcinoma [Phase 3]
A Phase 3 clinical trial update for LM-108 in combination with toripalimab versus paclitaxel for CCR8-positive gastric and gastroesophageal …
-
CLINICAL_TRIALS research · 2026-01-22Clinical Trial Update: First in Human Study of QLS5316 in Solid Tumors [Phase 1]
This is a first-in-human Phase 1 trial of QLS5316 in various solid tumors; the study is not yet recruiting.
-
CLINICAL_TRIALS trial_result · 2026-01-22Clinical Trial Update: Combination of Chemotherapy and Adaptive MR-Guided Radiotherapy to Improve Outcomes in Patients With Esophageal Adenocarcinoma [Phase 1]
A Phase 1 trial assessing the combination of chemotherapy and adaptive MR-guided radiotherapy for esophageal adenocarcinoma and gastroesopha…
-
CLINICAL_TRIALS other · 2026-01-22Clinical Trial Update: JS107 vs Investigator's Choice as Second-line or Later Therapy for Advanced CLDN18.2-Positive Gastricor GEJ Adenocarcinoma. [Phase 3]
Phase 3 clinical trial evaluating JS107 versus investigator's choice as second-line or later therapy for CLDN18.2-positive advanced gastric …
-
CLINICAL_TRIALS withdrawal · 2026-01-21Clinical Trial Update: Study Evaluating the Combination of Bemarituzumab + FLOT Chemotherapy in Perioperative Setting for Resectable Stage cT2-T4a or N+ Gastric and GEJ Adenocarcinoma Overexpressing FGFR2b [Phase 2]
A Phase 2 trial evaluating bemarituzumab in combination with FLOT chemotherapy for perioperative treatment of FGFR2b-overexpressing gastric/…
-
CLINICAL_TRIALS research · 2026-01-21Clinical Trial Update: A Study of Disitamab Vedotin Combined With Trastuzumab and Tislelizumab Versus Chemotherapy Combined With Trastuzumab With or Without Pembrolizumab in HER2-high Expression Advanced Gastric or Gastroesophageal Junction Adenocarcinoma. [Phase 3]
Phase 3 trial evaluating disitamab vedotin with trastuzumab and tislelizumab versus chemotherapy with trastuzumab (with or without pembroliz…
-
CLINICAL_TRIALS research · 2026-01-13Clinical Trial Update: First in Human Study of TORL-2-307-ADC in Participants With Advanced Cancer [Phase 1]
First-in-human phase 1 study of TORL-2-307-ADC in participants with advanced cancer, including gastric cancer, pancreatic cancer, and gastro…
-
CLINICAL_TRIALS research · 2026-01-12Clinical Trial Update: Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04) [Phase 3]
This clinical trial update reports the Phase 3 DESTINY-Gastric04 study of trastuzumab deruxtecan for HER2-positive gastric cancer or gastroe…
-
CLINICAL_TRIALS research · 2026-01-12Clinical Trial Update: Neoadjuvant Intra-tumoral RP2 and FLOT in Gastroesophageal Adenocarcinoma [Phase 2]
A Phase 2 neoadjuvant trial evaluating intra-tumoral RP2 in combination with the FLOT regimen for gastric and esophageal adenocarcinoma is l…
-
CLINICAL_TRIALS research · 2026-01-12Clinical Trial Update: Pembrolizumab and Lenvatinib for the Treatment of Advanced, Unresectable, or Metastatic Gastroesophageal Adenocarcinoma [EARLY_Phase 1]
A phase 1 trial is evaluating the combination of pembrolizumab and lenvatinib for advanced, unresectable, or metastatic gastric cancer and g…
-
CLINICAL_TRIALS research · 2026-01-12Clinical Trial Update: Fruquintinib Combined With Trastuzumab and XELOX as First-line Treatment in Patients With HER2-positive Advanced Gastric Cancer [Phase 1, Phase 2]
This clinical trial update describes a Phase 1/2 study evaluating Fruquintinib in combination with Trastuzumab and XELOX as first-line thera…
-
CLINICAL_TRIALS trial_result · 2026-01-09Clinical Trial Update: Induction FLOT With CROSS CRT for Esophageal Cancer [Phase 2]
A Phase 2 clinical trial evaluating induction FLOT chemotherapy followed by CROSS chemoradiation for esophageal or gastroesophageal junction…
-
CLINICAL_TRIALS research · 2026-01-07Clinical Trial Update: Bemarituzumab in FGFR2b+ Patients With Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction, Who Failed at Least One Prior Line of Palliative Chemotherapy [Phase 2]
Phase 2 clinical trial evaluating bemarituzumab in FGFR2b-positive advanced or metastatic stomach or gastroesophageal junction adenocarcinom…
-
CLINICAL_TRIALS research · 2026-01-06Clinical Trial Update: Hypofractionated Radiotherapy Plus Immunochemotherapy for Neoadjuvant Treatment of Gastroesophageal Junction Adenocarcinoma [Phase 1, Phase 2]
A Phase 1/2 trial evaluating hypofractionated radiotherapy plus immunochemotherapy as neoadjuvant treatment for gastroesophageal junction ad…
-
CLINICAL_TRIALS research · 2026-01-05Clinical Trial Update: Telehealth for the Self-Management of Dietary Quality of Life in Patients After Stomach Cancer Surgery [NA]
This update describes a telehealth program to help patients manage dietary quality of life after stomach cancer surgery; the study is curren…
-
CLINICAL_TRIALS research · 2025-12-31Clinical Trial Update: Hyperthermic Intraperitoneal Chemotherapy With Cisplatin and Paclitaxel for the Treatment of Patients With Gastric and Gastroesophageal Junction Adenocarcinoma at High Risk of Peritoneal Recurrence [Phase 2]
Phase 2 clinical trial evaluating hyperthermic intraperitoneal chemotherapy with cisplatin and paclitaxel for gastric or gastroesophageal ju…
-
CLINICAL_TRIALS research · 2025-12-31Clinical Trial Update: SHR-1701 + Rivoceranib (± SHR-2554) in Advanced GC After First-Line Immunotherapy Failure [Phase 2]
Phase 2 clinical trial evaluating SHR-1701 in combination with rivoceranib (± SHR-2554) for advanced gastric cancer and gastroesophageal jun…
-
CLINICAL_TRIALS withdrawal · 2025-12-26Clinical Trial Update: Zimberelimab + Domvanalimab in Gastroesophageal Adenocarcinoma [Phase 2]
A Phase 2 trial of zimberelimab plus domvanalimab in stomach and gastroesophageal junction adenocarcinoma has been withdrawn.
-
CLINICAL_TRIALS research · 2025-12-22Clinical Trial Update: Phase II RAINSPOT: Zolbetuximab-Paclitaxel-Ramucirumab for CLDN18.2 Positive Gastro-esophageal Cancer [Phase 2]
Phase II trial (RAINSPOT) evaluating zolbetuximab combined with paclitaxel and ramucirumab in CLDN18.2-positive gastric and gastroesophageal…